Fig. 8

a-b Analysis of the efficacy of doxycycline treatment in our microfluidic system. (ai) Quantification of hsp-6::gfp expression in young adult SJ4100 worms, treated on-chip with doxycycline at concentrations of 0, 15 and 30 μg/mL, starting from the L1 stage. (aii) Representative fluorescent pictures of young adult worms upon image thresholding, as used for the quantification of hsp-6::gfp expression. Scale bars = 200 μm. (bi) Quantification of the development time to the young adult stage in SJ4100 worms, treated on-chip with doxycycline at concentrations of 0, 15 and 30 μg/mL, starting from the L1 stage. (bii) Representative brightfield pictures of young adult worms, as used for the monitoring of the development time. Scale bars = 200 μm. c-d Temporal evolution of (c) the average size and (d) the average number of aggregates counted in AM725 worms, over a 60 h period upon the onset of young adult stage (set as t = 0). Different aggregation profiles are observed between untreated AM725 worms and the AM725 worms treated on-chip with doxycycline at 15 μg/mL concentration, starting from the L1 stage. Graphs are expressed as mean + SEM (N = 5). e-f Temporal evolution of worms’ motility over 7 days of adulthood, as observed on NGM plates for (e) doxycycline-treated vs. untreated AM725 worms and (f) mrps-5 RNAi-treated vs untreated AM725 worms